

SUBJECT INDEX

A

Acatalasemia
catalase deficiency and, 206
Acetaminophen
methemoglobinemia and, 4
nephrotoxicity of, 340-42
Acetanilide
major metabolite of, 3-4
methemoglobinemia and, 3
Acetophenetidin
See Phenacetin
N-Acetylaminopyrine
aminopyrine acetylation and,
5
Acetylcholine
coexistence with adenosine
triphosphate, 293
coexistence with vasoactive
intestinal peptide, 286
endothelium and, 45
galanin receptor activation
and, 300
gastric effects of, 270
inactivation of, 13
Purkinje fiber inward current
and, 64
release of
neuropeptides and, 166
thermoregulation and, 431-32
vascular smooth muscle and,
391-92
Acetylcholinesterase
acetylcholine inactivation and,
13
N-Acetylcysteine
doxorubicin therapy and, 200
hyperbaric oxygen toxicity
and, 203
N-Acetyl-p-aminophenol
acetanilide metabolism and,
3-4
phenacetin metabolism and, 4
See also Acetaminophen
N-Acetylprocainamide
early afterdepolarizations and,
72
N-Acetylserotonin, 19
5-methoxy-N-Acetyltryptamine
See Melatonin
Aconitine
early afterdepolarizations and,
72
Acquired immune deficiency
syndrome, 411-25
etiologic agent of, 411-13
heroin addicts and, 481-83
ACTH
See Adrenocorticotropin

Adenosine
erythropoietin production and,
103-4
Adenosine A1 agonists
renin secretion and, 107
Adenosine receptor
renal, 103-4
Adenosine triphosphate
coexistence with acetylcho-
line, 293
endothelium and, 45
epinephrine metabolism and,
12-13
S-Adenosylmethionine
catecholamine O-methylation
and, 12-13
histamine methylation and,
18
Adenylate cyclase
adenosine receptor and, 104
dopamine and, 216, 353
dynorphin and, 133
Adenyl cyclase
blood-brain barrier peptide re-
ceptors and, 29
brain capillary
activation of, 30
 β -Adrenergic agonists
erythropoietin production and,
111
 β -Adrenergic blockers
erythropoietin production and,
111
serotonin N-acetyltransferase
and, 21
 α -Adrenergic receptor
hunger and, 248
 β -Adrenergic receptor
melatonin synthesis and, 21
norepinephrine and, 21
Adrenochrome
schizophreniclike hallucina-
tions and, 12
Adrenocorticotropin
neuromodulatory action of,
164
phenylethanolamine-N methyl-
transferase and, 18
stress hormones and, 22
Agranulocytosis
dapsone and, 239
suramin and, 420
AIDS
See Acquired immune de-
ficiency syndrome
AIDS-related complex, 411
Albumin
blood-brain barrier and, 30-
31, 34-35

Alinidine
Purkinje fiber inward current
and, 64
Alkylating agents
erythropoietin production and,
111
Allergy
drug cytotoxicity and, 372-
75
N-Allylnormetazocine
thermoregulation and, 433
Aluminum
Alzheimer's disease and,
29
Alzheimer's disease
bethanechol and, 32
neuritic plaque in
aluminum and, 29
amyloid peptide and, 30
Amenorrhea
hyperprolactinemia and, 354
Amikacin
nephrotoxicity of, 332
Amiloride
early afterdepolarizations and,
72
Amines
biogenic
depression and, 16-17
protonatable
H,K-ATPase and, 281-82
sympathomimetic, 5-6
norepinephrine uptake and,
16
Amino acid receptors
excitatory
allosteric modulation of,
462-65
gamma-Aminobutyric acid re-
ceptor
endogenous allosteric mod-
ulators of, 452-62
Aminoglycosides
nephrotoxicity of, 332-35
Aminopeptidase
brain capillary, 30
Aminophylline
cerebrovasospasm and, 316
4-Aminopyridine
palytoxin and, 146
Aminopyrine
N-demethylation of, 8
methylation products of, 5
Amitriptyline
coexisting neurotransmitters
and, 302
Ammonium antimony tungstate
human immunodeficiency
virus and, 421-22

- Amphetamine
anorectic effect of, 248, 257-59
behavioral effects of, 5
metabolism of, 6
microsomal enzymes and, 6-8
norepinephrine uptake and, 16
paranoid psychosis due to, 17
water intake and, 262
- Amphotericin B**
human immunodeficiency virus and, 417-19
nephrotoxicity of, 335-36
- Amygdaloid kindling**
dynorphin and, 129
- Amyloid peptide**
Alzheimer's disease and, 30
- Analgesia**
dynorphin and, 124-26
- Analgesics**
nonaspirin
methemoglobinemia and, 3
- Anaphylaxis**
drug allergy and, 368, 372
- Androgens**
erythropoietin production and, 111
- Anemia**
aplastic
chloramphenicol and, 83, 87, 89-90, 94
hemolytic
dapsone and, 239
drug allergy and, 368
enzyme deficiencies and, 205
suramin and, 420
- Anemia of chronic kidney failure**
erythropoietin and, 113
- Anemonia sulcata**
toxin-II of, 147
- Angina pectoris**
ketanserin and, 52
- Angiotensin**
cerebrovasospasm and, 323
hypertension and, 41
- Angiotensin-converting enzyme**
brain capillary, 30
Angiotensin II
blood-brain barrier and, 30
cyclosporine A and, 338-39
erythropoietin production and, 111
neuromodulatory action of, 164
- Aniline**
hydroxylation of, 8
methemoglobinemia and, 3
- Anorectics**
endogenous, 247-63
- Anthopleura xanthogrammica**
anthopleurin-A of, 147
- Anthopleurin-A**, 147
- Antiarrhythmics**
sinus node and, 64-65
- Antidepressants**
coexisting neurotransmitters and, 301-2
norepinephrine uptake and, 16
- Antiflammatory agents**
cerebrovasospasm and, 319-20
- Antioxidant defense systems**, 189-206
- Antioxidants**
anticarcinogenic properties of, 204
gentamicin-induced lipid peroxidation and, 334
- Antipsychotics**
See Neuroleptics
- Antipyrene**
body water measurement and, 4
metabolites of, 4
- Antithrombin III**
cerebrovasospasm and, 323
- Apamin**
palytoxin and, 146
- Aplastic anemia**
chloramphenicol and, 83, 87, 89-90, 94
- Arachidonic acid**
eicosanoid synthesis and, 106
- Arginine vasopressin**
neuromodulatory action of, 164
- Aromatic amino acid decarboxylase**
L-DOPA and, 223
- Arrhythmogenesis**
abnormal automaticity in, 68-75
- Arthritis**
drug allergy and, 374
- Ascorbate**
host antioxidant defense and, 195
- Ascorbic acid**
drug metabolism and, 5
- Aspartame**
hyperphenylalaninemia and, 28
- Aspirin**
nephrotoxicity of, 342
- Asthma**
drug allergy and, 368, 372
- Astroglial cells**
benzodiazepine recognition sites in, 458
- Atherosclerosis**
hypercholesterolemia and, 47
serotonin and, 46-47
- ATP**
See Adenosine triphosphate
- Atriopeptin**
brain capillary guanyl cyclase and, 30
- Atropine**
coexisting neurotransmitters and, 301
gastric acidity and, 269-70
- Autonomic nervous system**
neuromodulation of, 179-80
- Avanol**
human immunodeficiency virus and, 416-17
- Avarone**
human immunodeficiency virus and, 416-17
- Azidothymidine**
human immunodeficiency virus and, 420-21
- B**
- Bacillus subtilis**
chloramphenicol-resistant, 86
- Bacteroides fragilis**
chloramphenicol and, 84, 87
- Barbiturates**
oxidation of, 8
- Batrachotoxin**
sodium channel and, 143
- Benzimidazoles**
substituted
H,K-ATPase and, 274-81
- Benzodiazepine recognition sites**
endogenous ligands for, 452-62
- Benzodiazepines**
tolerance to, 461
- Benzpyrine**
glucuronide conjugation and, 11
- Beta-agonists**
Purkinje fiber inward current and, 64
- Bethanechol**
Alzheimer's disease and, 32
- Bilirubin**
host antioxidant defense and, 197-98
metabolism of
glucuronic acid conjugation and, 11
- Biogenic amines**
depression and, 16-17
- Bismuth**
duodenal ulcer and, 270
- Blood-brain barrier**, 25-35
catecholamines and, 16
cell biology of, 26

- dopamine antagonists and, 352
 drug delivery across, 32-35
 fluorodopa and, 224
 glial induction model of, 26
 neuroleptics and, 220
 transport across
 carrier-mediated, 27-29
 plasma-mediated, 30-32
 receptor-mediated, 29-30
 tritium-labeled epinephrine and, 14
 Blood pressure
 dynorphin and, 126
 neuromodulation of, 165, 179
 B lymphocytes
 immunogens and, 370-71
 Body temperature
 dynorphin and, 127
 neuroregulation of, 165, 179, 431-32
 opioid peptides and, 429-44
 endogenous, 439-41
 exogenous, 432-39
 Body water
 measurement of
 antipyrrine and, 4
 Bombesin
 anorectic effect of, 249-50
 neuromodulatory action of, 164
 Bone marrow suppression
 azidothymidine and, 421
 chloramphenicol and, 87-89
 thiamphenicol and, 88
 Bradykinin
 angiotensin-converting enzyme and, 30
 endothelium and, 45
 vascular smooth muscle and, 391
 Brain
 dynorphin and, 124-25
 See also Blood-brain barrier
 Brain tumor
 blood-brain barrier of, 26
 Brevetoxins, 141-43
 Bronchitis
 tobacco smoke and, 201
 Bupivacaine
 blood-brain barrier and, 31
 Burst forming unit erythroid colony cell
 erythropoietin and, 110
Buthus euepeus
 toxins of, 147-48
 Butoxamine
 erythropoietin production and, 112
 Butyrophophenes
 antipsychotic potency of, 347
- C
- Caerulein
 anorectic effect of, 249
 Caeruloplasmin
 Wilson's disease and, 206
 Caffeine
 physiologic disposition of, 5
 Calcitonin
 anorectic effect of, 259-63
 water intake and, 262
 Calcitonin gene related peptide
 neuromodulatory action of, 164
 Calcium
 erythropoietin production and, 106-8
 prolactin release and, 353
 Calcium channel agonists
 renin secretion and, 107
 Calcium channel antagonists
 cerebrovasospasm and, 320-21
 Calcium channels
 vascular smooth muscle and, 393-96
 Calcium ionophore A23187
 renin secretion and, 107
 Calmodulin
 anorectic effect of, 249-50
 prolactin release and, 353
 Cancer
 host antioxidant defense systems and, 204
 Candicidin
 human immunodeficiency virus and, 418
 Capsaicin
 neurotransmitter release and, 296
 Captopril
 drug-carrier conjugates of, 369
 vasoactive peptide metabolism and, 30
 Carboxymethyltransferase, 18
Carcharhinus menisorrhina
 ciguatoxin of, 144
 Cardiac cellular electrophysiology, 61-75
 Cardiac glycosides
 delayed afterdepolarizations and, 70
 palytoxin and, 146-47
 Cardiac muscle
 delayed rectifier in, 62-63
 palytoxin and, 146
 sea anemone toxins and, 148
 Cardiomyopathy
 doxorubicin and, 199-200
 Cardiovascular system
 dynorphin and, 126-27
- β -Carotene
 host antioxidant defense and, 197
 Catalase
 host antioxidant defense and, 193
 Catalase deficiency
 acatalasemia and, 206
 Catecholamines, 11-18
 blood-brain barrier and, 16
 coexistence with opioid peptides, 293
 delayed afterdepolarizations and, 71
 depression and, 17
 early afterdepolarizations and, 72
 feeding behavior and, 248
 inactivation of, 13-14
 metabolism of
 pathways of, 13
 O-methylation of, 12-13
 release of
 neuropeptides and, 166
 selective uptake of, 14
 synthesis of
 tyrosine and, 223
 toxicity of, 324
 Catechol-O-methyltransferase
 tissue distribution of, 13
 Catechols
 O-methylation of, 13
 Cathepsins
 erythropoietin production and, 106
 Central nervous system
 dynorphin and, 130-31
Centruroides sculpturatus
 β -toxins of, 143
 Cephaloglycin
 nephrotoxicity of, 337
 Cephaloridine
 nephrotoxicity of, 337
 Cephalosporins
 nephrotoxicity of, 336-37
 Cephalothin
 nephrotoxicity of, 337
 Cerebral blood supply
 serotonin and, 53
 Cerebrovasospasm, 311-25
 acute, reversible, 321-24
 animal models of, 314
 chronic
 pathogenesis and
 pathophysiology of, 312-14
 subarachnoid hemorrhage and, 318-21
 chronic, irreversible, 314-18
 subarachnoid hemorrhage and, 53, 311

- Cesium
early afterdepolarizations and, 72-75
- Chaulmoogra oil
leprosy and, 233
- Chemotaxis
mononuclear cell
opioid peptides and, 130
- Chlamydia
chloramphenicol and, 84
- Chloramphenicol, 83-96
actions of, 87-88
antimicrobial, 84-87
aplastic anemia and, 83, 87, 89-90, 94
bacterial resistance to, 86-87
bone marrow suppression and, 87-89
DNA synthesis and, 90-91
erythroid sensitivity to, 89
hematotoxicity of, 87
metabolism of, 92-94
structure of, 85
toxicity of, 87-94
- nitroso-Chloramphenicol
cytotoxicity of, 90
DNA damage and, 91-92
- Chloramphenicol acetyltransferase
chloramphenicol-resistant bacteria and, 86
- Chlorhexidine
drug-carrier conjugates of, 372
- Chlormopramine
coexisting neurotransmitters and, 302
growth hormone secretion and, 356
- Cholecystokinin
anorectic effect of, 249-51
neuromodulatory action of, 164
- Chronic cerebrovasospasm
See Cerebrovasospasm
- Chymotrypsin
erythropoietin and, 102
- Cigarette smoking
See Tobacco smoke
- Ciguatera fish poisoning, 141, 143-44
- Ciguatoxin, 141, 143-45
- Cimetidine
gastric acidity and, 270
- Cinanserin
serotonin and, 48
- Circulatory system
dynorphin and, 127
- Clofazimine
leprosy and, 236-39
- Clozapine
coexisting neurotransmitters and, 302
- Cobalt
erythropoietin production and, 107, 111
- Cocaine
norepinephrine uptake and, 16
- Computer simulation
pacemaker potential and, 66-68
- Conjugation
catecholamine metabolism and, 13
- drug metabolism and, 6
- Conotoxins, 150-55
- Conus geographus*
neurotoxin of, 141
venom of, 150
- Conus* spp.
toxins of, 150-55
- Copper
host antioxidant defense and, 196
- Copper superoxide dismutase, 192-93
- Coronary artery spasm
ischemic heart disease and, 36
- Coronary artery tree
serotonin and, 50-53
- Corticotropin releasing factor
neuromodulatory action of, 164
- Corticotropin releasing hormone
anorectic effect of, 250
- Ctenochætus striatus*
maitotoxin of, 144
- Cyclic AMP
dopamine and, 216
erythropoietin production and, 103-4
melatonin synthesis and, 21
- Cyclic GMP
melatonin synthesis and, 21
- Cyclic nucleotides
erythropoietin production and, 111
- Cyclosporine
human immunodeficiency virus and, 422-23
- Cyclosporine A
nephrotoxicity of, 338-40
- Cytochrome P-450
reactive oxygen metabolites and, 190
- Cytochrome P-450 monooxygenases, 8
- Cytotoxicity
drug
allergic mechanisms of, 372-75
- D
- Dapsone
leprosy and, 237-39
side effects of, 239
- Dapsone syndrome, 239
- Dazoxiben
ischemic heart disease and, 52
- Deamination
catecholamine metabolism and, 13
- drug metabolism and, 6
- Demethylation
drug metabolism and, 6
- Deoxypentenone
anorectic effect of, 250
- Deoxytetrotonate
anorectic effect of, 250
- Depression
catecholamine hypothesis of, 17
- Dermatitis
drug allergy and, 368
- Dexamethasone
phenylethanolamine-N methyltransferase and, 18
- Diacylglycerol
erythropoietin production and, 105, 107-8
- Diazepam
benzodiazepine recognition sites and, 454
- Dicoumerol
measurement in plasma, 5
- 2',3'-Dideoxycytidine
human immunodeficiency virus and, 421
- Diethylmaleate
doxorubicin cytotoxicity and, 199
- Dihydropyridine
vascular smooth muscle and, 395
- Diisocyanates
drug-carrier conjugates of, 369
- Diisothiocyanates
drug-carrier conjugates of, 369
- Diltiazem
cerebrovasospasm and, 320-21
- N,N-Dimethyltryptamine, 18
- Diquat
cytotoxicity of, 200-1
reactive oxygen metabolites and, 191
- Diuretics
mercurial
erythropoietin production and, 111

- DNA repair mechanisms
host antioxidant defense and, 198-99
- DNA synthesis
chloramphenicol and, 90-91
- DNA transcription
human immunodeficiency virus and, 423-24
- Domperidone
prolactin secretion and, 352
- L-DOPA
aromatic amino acid de-carboxylase and, 223
blood-brain barrier and, 34
growth hormone secretion and, 355
- O-methylation of, 13
- α -methyl-DOPA
blood-brain barrier and, 34
- Dopamine
adenylate cyclase and, 216, 353
endogenous
measurement of, 10
growth hormone secretion and, 354-55
maitotoxin and, 144
measurement in brain nuclei, 18
- O-methylation of, 13
- Parkinson's disease and, 225
- prolactin secretion and, 350
- thyrotropin secretion and, 356-57
- Dopamine agonists
hyperprolactinemia and, 351
- Dopamine- β -hydroxylase
intraneurial storage of, 15
- tyrosine hydroxylase and, 17
- Dopamine receptor
biochemistry of, 216-23
growth hormone secretion and, 355-56
- neuroleptics and, 216-17, 347-50
- prolactin secretion and, 351-52
- thyrotropin secretion and, 358
- Down's syndrome
dopamine β -hydroxylase and, 15
- Doxorubicin
cardiotoxicity of, 199-200
reactive oxygen metabolites and, 191
- Drug cytotoxicity
allergic mechanisms of, 372-75
- Drug hypersensitivity, 367-82
- Drug metabolism
ascorbic acid and, 5
pathways of, 6
- Drug-metabolizing enzymes, 6-10
- Drug nephrotoxicity, 331-42
- Duodenal ulcer disease
drugs for, 270
- Dynorphin, 123-33
action of
molecular basis of, 13133
thermoregulation and, 440
in vitro effects of, 130-31
in vivo effects of, 124-30
- Dynorphin receptor
second messengers and, 132-33
- Dysautonomia
familial
dopamine β -hydroxylase and, 15
- E
- Eburnetoxin, 150, 154
- Eglin C
antiemphysemic activity of, 201
- Eicosanoids
erythropoietin production and, 106
- Emphysema
 α -1-antiprotease deficiency and, 206
tobacco smoke and, 201
- Endopeptidase lysine-C
erythropoietin and, 102
- β -Endorphin
anticonvulsant effects of, 129
blood-brain barrier and, 34-35
blood pressure/heart rate and, 126
stress and, 129
thermoregulation and, 440
- β -Endorphin receptor, 123
- Endothelium
platelet aggregation and, 44-45
serotonin and, 44-46
- Met-Enkephalinamide
thermoregulation and, 440
- Enkephalin receptor, 123
- Enkephalins
brain capillary endopeptidase and, 30
- Enterococci
chloramphenicol and, 84
- Enterogastrone
anorectic effect of, 250
- Enzymes
drug-metabolizing, 6-10
host antioxidant defense and, 192-94
- Ephedrine
behavioral effects of, 5
- metabolism of, 6
microsomal enzymes and, 7-8
SKF525A and, 8
- Epinephrine
cerebrovasospasm and, 323
endogenous
measurement of, 10
metabolism of, 12-14
schizophrenia and, 12, 14
O-methyl metabolite of, 13
thermoregulation and, 433
- Epizanthus arenaceus*
zoanthoxanthins of, 145
- Ergonovine
ischemic heart disease and, 36
- Erythema nodosum leprosum, 233
- thalidomide and, 240
- Erythroid colony forming unit
erythropoietin and, 110
- Erythromycin
leprosy and, 233, 236
- Erythropoietin, 101-15
assay of, 102-3
pharmacokinetics of, 112-13
physicochemical characterization of, 102
production of
extrarenal, 109-10
pharmacologic agents and, 111-12
renal, 103-6, 108-9
secretion of
calcium and, 106-8
sites of action of, 110-11
therapeutic uses of, 113-14
- Escherichia coli*
chloramphenicol-resistant, 86
- Estradiol
narcotic demethylation and, 9
- Estrogens
erythropoietin production and, 111
- Ethionamide
leprosy and, 240
- Ethylene oxide
drug-carrier conjugates of, 369
- Etylketazocine
thermoregulation and, 433
- Exocytosis
catecholamine discharge and, 15
- F
- Familial dysautonomia
dopamine β -hydroxylase and, 15

- Famotidine
gastric acidity and, 270
- Feeding behavior
dynorphin and, 127-28
monoamines and, 247-48
opioid peptides and, 258-59
- Fenfluramine
anorectic effect of, 248, 257-59
- Ferritin
host antioxidant defense and, 196
- Ferrochelatase
erythroid sensitivity to chloramphenicol and, 89
- Fibrin
cerebrovasospasm and, 323
- Fibrinogen
cerebrovasospasm and, 323
- Flumazenil
benzodiazepine recognition sites and, 454
- Fluorodops
blood-brain barrier and, 224
- FMRFamide
neuromodulatory action of, 164
- Food deprivation
hunger drive and, 252
- Formaldehyde
drug-carrier conjugates of, 369
- Foscarnet
human immunodeficiency virus and, 419-20
- Free fatty acid metabolites
anorectic effect of, 250
- Free fatty acids
blood-brain barrier and, 30-31
- G**
- Galactose
satiety and, 254
- Galamin
neuromodulatory action of, 164
- Galamin receptor
acetylcholine and, 300
- Gambierdiscus toxicus*
ciguatoxin of, 144
- Gastric acid secretion
inhibition of
omeprazole and, 274
- Gastric ulcer disease
drugs for, 270
- Gastrin
gastric effects of, 270
- Gastroesophageal reflux disease
drugs for, 270
- Gentamicin
nephrotoxicity of, 332-34
- Geographotoxin, 150
- Glia cells
DBI-like immunoreactivity in, 457
neuropeptides and, 178
- Globulins
blood-brain barrier and, 30
- Glomerular filtration rate
gentamicin therapy and, 334
- Glomerulonephritis
drug allergy and, 374
- Glucagon
anorectic effect of, 250
- Glucose
blood-brain barrier and, 27
satiety and, 253-54
- Glucose-6-phosphate
amphetamine metabolism and, 7
- Glucose-6-phosphate dehydrogenase deficiency
dapsone and, 239
- hemolytic anemia and, 205
- Glucosulfone sodium
leprosy and, 233
- Glucuronic acid conjugation
bilirubin metabolism and, 11
- Glucuronides
phenolic
uridine diphosphate glucuronic acid and, 10
- synthesis of
congenital jaundice and, 11
- Glutathione
host antioxidant defense and, 194-95
- Glutathione peroxidase
selenium-dependent
host antioxidant defense and, 193-94
- Glutathione reductase deficiency
hemolytic anemia and, 205
- Glutathione transferase
host antioxidant defense and, 196-97
- Goniopora* toxins, 149-55
- Granulocyte colony stimulating factor
burst forming unit erythroid colony cell and, 110
- Granulocytopenia
drug allergy and, 368
- Growth hormone
erythropoietin production and, 111
secretion of
neuroleptics and, 354-56
- Guanyl cyclase
blood-brain barrier peptide receptors and, 29
- brain capillary activation of, 30
- Gymnodinium breve*
See *Ptychodiscus brevis*
- Gymnothorax javanicus*
ciguatoxin of, 144
- H**
- Haloperidol
coexisting neurotransmitters and, 302
- Halothane hepatitis, 378-80
- Hansen's disease
See Leprosy
- Heart rate
dynorphin and, 126
- Hematopoietic system
chloramphenicol and, 87
- Hemoglobin
cerebrovasospasm and, 323
host antioxidant defense and, 194
reactive oxygen metabolites and, 190
- Hemolysis
palytoxin and, 146
- Hemolytic anemia
dapsone and, 239
- drug allergy and, 368
- enzyme deficiencies and, 205
- Hemophilus influenzae*
ampicillin-resistant
chloramphenicol and, 83-84
- chloramphenicol-resistant, 86
- Hepatitis
drug allergy and, 368
- halothane, 378-80
- Hepatocytes
lipid peroxidation in
bipyridilium herbicides and, 192
- menadione and, 191
- Heroin addicts
acquired immune deficiency syndrome and, 481-83
- Hexabarbital
metabolism of
SKF525A and, 8
- sleeping time of, 8
- Histamine
cerebrovasospasm and, 320
- dynorphin and, 129
- enzymatic N-methylation of, 18
- gastric acidity and, 270
- measurement in brain nuclei, 18
- vascular smooth muscle and, 391
- Histamine N-methyltransferase, 18

- H,K-ATPase, 270-74
selective inhibition of, 274-82
- Hormones**
blood-brain barrier and, 27-31
dynorphin and, 128-29
release of
peptides and, 165
transduction mechanisms of, 22
- Host antioxidant defense systems, 192-99
- HPA-23
human immunodeficiency virus and, 421-22
- Human immunodeficiency virus, 411-13
- Hunger**
 α -adrenergic receptor and, 248
- Hunger drive
food deprivation and, 252
- Hydroperoxide**
cerebrovasospasm and, 323
- 5-Hydroxytryptamine
See Serotonin
- 4-Hydroxyantipyrine
antipyrene metabolism and, 4
- 6-Hydroxydopamine
tyrosine hydroxylase and, 17
- Hydroxyindole-O-methyltransferase, 18-19
- Hydroxylation**
drug metabolism and, 6
- Hyperaminoacidemia
blood-brain barrier and, 28
- Hypercholesterolemia
atherosclerosis and, 47
- Hypergastrinemia
Zollinger-Ellison syndrome and, 269, 281
- Hyperglycemia
blood-brain barrier glucose transporter and, 27
- Hyperkalemia
cyclosporine A and, 339
- Hyperphenylalaninemia
blood-brain barrier and, 28
- Hyperprolactinemia
dopamine agonists and, 351
effects of, 353-54
- Hypersensitivity
drug, 367-82
- Hypertension**
angiotensin and, 41
dopamine β -hydroxylase and, 15
vascular smooth muscle membrane in, 389-404
- Hyperthermia
drug-induced, 433-39
- Hypocholesterolemia
serotonin and, 47
- Hypothalamus**
neuroleptics and, 353
- Hypothermia**
drug-induced, 433-39
- Hypothyroidism
bradycardia in
triiodothyronine and, 28-29
- I**
- Ibuprofen
cerebrovasospasm and, 319-20
- Imipramine
coexisting neurotransmitters and, 302
- Imipramine recognition sites
endogenous ligands for, 465-69
- Immune complex disease
drug hypersensitivity and, 374
- Immune response
drug-induced, 368-70
- Immune system
endogenous opioids and, 130
- Immunogens
B lymphocytes and, 370-71
T lymphocytes and, 371-72
- Immunoglobulins
drug hypersensitivity and, 372
- Immunomodulation
dynorphin and, 130
- Inflammation
dynorphin and, 129
host antioxidant defense systems and, 204-5
- Inositol triphosphate
erythropoietin production and, 104
- Insulin
anorectic effect of, 250
blood-brain barrier and, 29
neuromodulatory action of, 164
- Interleukin 3
burst forming unit erythroid colony cell and, 110
- Ion channels
regulation of
peptides and, 176-77
- Iron superoxide dismutase, 192
- Ischemic heart disease
coronary artery spasm and, 36
- Isocitric acid
amphetamine metabolism and, 7
- 1-Isoproterenol
 β -adrenergic receptor and, 21
- J**
- Jaundice
congenital
- glucuronide synthesis and, 11
- K**
- Ketanserin
angina pectoris and, 52
cerebral artery spasm and, 53
platelet activation and, 52
platelet aggregation and, 43-44
- Raynaud's phenomena and, 54
- renal vasoconstriction and, 55
- serotonin receptor and, 42
- vasoconstriction and, 51
- Ketanserin recognition sites
endogenous ligands for, 465-69
- Kidney**
erythropoietin production in, 103-6, 108-19
serotonin and, 54-55
- Kidney failure
anemia of
erythropoietin and, 113
gentamicin-induced, 333-34
- L**
- Lactoferrin
host antioxidant defense and, 196
- Lactoperoxidase
host antioxidant defense and, 194
- Lanthanum
maitotoxin and, 144
- Leiurus quinquestriatus*
neurotoxins of, 143, 147-48
- Lepra reactions, 232
- Leprosy
chemotherapy of, 231-42
lepromatous, 232
paucibacillary, 237
tuberculoid, 232
type 2 reactions in, 233
- Lidocaine
blood-brain barrier and, 33
cardiac delayed rectifier and, 63
- Purkinje fiber inward current and, 64
- Light
melatonin synthesis and, 20
- Liposomes
drug delivery and, 33
- Liver**
erythropoietin production in, 109-10

- LSD
fluorometric assay for, 10
metabolism of, 12
- Lung disease
tobacco smoke and, 201-2
- Lupus erythematosus-like syndrome
drug allergy and, 368, 374
- Luteinizing hormone
opioids and, 128
- Luteinizing hormone releasing hormone
neuromodulatory action of, 164
- Lutjanus bohar*
ciguatoxin of, 144
- Lymphocytes
opioid receptors on, 130
- Lymphokines
opioid peptides and, 130
- M
- Macrophage colony stimulating factor
burst forming unit erythroid colony cell and, 110
- Ma huang*, 6, 478
- Maitotoxin, 141, 143-45
- Manganese superoxide dismutase, 192
- Mannose
satiety and, 254
- Marine neurotoxins, 141-56
- Materia medica*, 477-78
- Mazindol
anorectic effect of, 248, 258
- Melanin inhibiting hormone
neuromodulatory action of, 164
- Melatonin
biosynthetic pathway of, 19-22
gonad inhibition and, 20
hydroxyindole-O-methyltransferase and, 18
synthesis of, 20-21
light and, 20
- Melphalan
See Phenylalanine mustard
- Membrane potential peptides and, 176
- Menadione
reactive oxygen metabolites and, 191
- Meningioma
blood-brain barrier of, 26
- Meningitis
chloramphenicol and, 84
- Meperidine
N-demethylation of, 8-9
- Mescaline
behavioral effects of, 5
- Metabolic alkalosis
cyclosporine A and, 339
- Metal ion chelators
hereditary deficiencies in, 206
host antioxidant defense and, 196
- Metanephrine
formation of, 13
- Methadone
N-demethylation of, 8-9
- Methemoglobinemia
nonaspirin analgesics and, 3
- Methionine
epinephrine metabolism and, 12-13
- Methiothepin
coronary artery tree and, 51
- Methylamphetamine
metabolism of, 6
- O-Methylation
catecholamine metabolism and, 13
- 3-Methylcholanthrene
glucuride conjugation and, 11
- α-Methylparatyrosine
blood-brain barrier and, 34
- Methylprednisolone
cerebrovasospasm and, 319-20
- N-Methyltransferase, 18
- Methyltransferases, 18
- Metronidazole
mutagenic activity of, 92
- Microsomes
drug-metabolizing enzymes of, 6-10
- Mineralocorticoids
vascular smooth muscle and, 401
- Monoamine oxidase
epinephrine metabolism and, 12
- Monoamine oxidase inhibitors
antidepressant actions of, 16
- Monoamines
feeding behavior and, 247-48
- Morphception
blood pressure/heart rate and, 126
- Morphine
analgesic effects of
dynorphin and, 124
anticonvulsant effects of, 129
N-demethylation of, 8-9
enzymatic conjugation of, 10-11
hypothermic effects of, 127
stroke and, 129
thermoregulation and, 432-39
- Motor system
dynorphin and, 126
- Mucopolypeptides
host antioxidant defense and, 196
- Mycobacterium leprae*
leprosy and, 231-33
- Mycoplasmas
chloramphenicol and, 84
- Mycloperoxidase
host antioxidant defense and, 194
- Myocytes
delayed rectifier in, 62-63
- N
- NADPH-cytochrome P-450 reductase
reactive oxygen metabolites and, 190
- NADPH:quinone oxidoreductase
host antioxidant defense and, 194
- Naloxone
dynorphin and, 126
feeding behavior and, 127
stroke and, 129
- Narcotics
N-demethylation of
sex difference in, 8-9
enzymatic conjugation of, 11
metabolism of, 12
tolerance to
mechanism of, 9
- Natural killer cells
opioid peptides and, 130
- Neisseria meningitidis*
chloramphenicol and, 84
- Neomycin
nephrotoxicity of, 333
- Nephritis
drug allergy and, 368
- Nephrotoxicity
drug, 331-42
- Nerve fibers
palytoxin and, 146
- Netilmicin
nephrotoxicity of, 332
- Neuroblastoma
torsion dystonia
dopamine β-hydroxylase and, 15
- Neurokinin A
serotonergic neurons and, 288
- Neuroleptics
blood-brain barrier and, 220
coexisting neurotransmitters and, 302
dopamine receptor and, 216-17, 347-50
growth hormone secretion and, 354-56

- hyperprolactinemia and, 351-52
neuroendocrine function and, 347-59
prolactin secretion and, 350-54
thyrotropin secretion and, 356-58
- Neuromodulation**
peptide, 163-80
diversity of, 168-70
mechanisms for, 174-78
neurotransmitters and, 167-68
specificity of, 165-67
- Neuromuscular junction**
sea anemone toxins and, 147
- Neurons**
DBI-like immunoreactivity in, 457
dynorphin and, 130-31
sea anemone toxins and, 148
- Neuropeptides**
coexisting
biosynthesis of, 291-92
colocalization with
neurotransmitters, 167-68
- Neuropeptide Y**
food and water intake and, 250-51
neuromodulatory action of, 164
- Neurotensin**
anorectic effect of, 250
neuromodulatory action of, 164
- Neurotoxins**
marine, 141-56
- Neurotransmitters**
biochemistry of
in vivo assessment of, 213-26
coexisting, 18
biosynthesis of, 289-93
chronic drug treatment and, 301-2
examples of, 288-89
release of, 293-301
storage and transport of, 292-93
synaptic interactions of, 302-4
types of, 287-88
colocalization with
neuropeptides, 167-68
inactivation of, 13-14
release of
peptides and, 165
transduction mechanisms of, 22
- Neutropenia**
azidothyimidine and, 421
- Nickel**
erythropoietin production and, 111
- Nicotinamide**
benzodiazepine recognition sites and, 455
- Nicotine**
thermoregulation and, 433
- Nifedipine**
cerebrovasospasm and, 316
- Nimodipine**
palytoxin and, 146
- Nisoldipine**
cardiac delayed rectifier and, 63
- Norepinephrine**
cerebrovasospasm and, 320, 323
- endogenous**
measurement of, 10
intraneuronal storage of, 15
maitotoxin and, 144
measurement in brain nuclei, 18
melatonin synthesis and, 20-21
- O-methylation of, 13**
- β-receptor and, 21**
- selective uptake of, 14**
- thermoregulation and, 431-32**
- toxicity of, 324**
- uptake of**
drugs blocking, 16
- Normetanephrine, 13**
- O**
- Obesity**
pharmacotherapy for, 247-48
- Octopamine**
localization of, 18
- Omeprazole**
gastric acid secretion and, 274
mechanism of action of, 275-79
- pharmacokinetics of, 275**
- toxicology of, 279-80**
- Opioid peptides**
body temperature and, 429-44
coexistence with catecholamines, 293
- endogenous**
classes of, 123
immune system and, 130
thermoregulation and, 439-41
- exogenous**
thermoregulation and, 432-39
- feeding behavior and, 258-59**
- hormones and, 128**
- neuromodulatory action of, 164**
- stroke and, 129**
- Opioid receptors**
classes of, 123, 131-32
dynorphin and, 130-31
- Oubain**
palytoxin and, 146-47
- renin secretion and, 107**
- Oxidation**
catecholamine metabolism and, 13
- Oxidoreductases**
protein-specific host antioxidant defense and, 198
- Oxygen**
high concentrations of biologic systems and, 203
- Oxytocin**
dynorphin and, 128
neuromodulatory action of, 164
- P**
- Pacemaker potential**
Purkinje fibers and, 63-68
- Palythoa spp.**
palytoxin of, 145-46
- Palytoxin, 141, 145-47**
- Pancreatic polypeptide**
anorectic effect of, 250
- Pancytopenia**
chloramphenicol and, 87
- Papaverine**
cerebrovasospasm and, 316
- Paragracine, 145**
- Parquat**
cytotoxicity of, 200-1
reactive oxygen metabolites and, 191
- Parathyroid hormone**
brain capillary adenylyl cyclase and, 30
- Parazoanthus axinellae**
zoanthoxanthins of, 145
- Parazoanthus gracilis**
paragracine of, 145
- Parkinson's disease**
dopamine depletion in, 225
experimental, 33
- Penicillamine**
drug-carrier conjugates of, 369
Wilson's disease and, 206
- D-Penicillamine**
human immunodeficiency virus and, 415
- Penicillin**
drug-carrier conjugates of, 369

- Pentazocine
thermoregulation and, 433
- Pentylenetetrazol
convulsant effects of
opioids and, 129
- Peptic ulcer disease
drugs for, 270
- Peptides
chimeric
blood-brain barrier and, 34
endogenous
anorectic effect of, 249-51
neuromodulation by, 163-80
diversity of, 168-70
mechanisms for, 174-78
neurotransmitters and, 167-68
specificity of, 165-67
See also Opioid peptides
- Peroxidases
host antioxidant defense and, 194
- Phenacetin
metabolites of, 4
methemoglobinemia and, 3
nephrotoxicity of, 340-42
- Phencyclidine binding sites
endogenous ligands for, 462-65
- p-Phenetidine
phenacetin metabolism and, 4
- Phenothiazines
antipsychotic potency of, 347
- Phenylalanine mustard
blood-brain barrier and, 34
- Phenylenediamine
gentamicin-induced lipid peroxidation and, 334
- Phenylephrine
coronary artery vasoconstriction and, 52
- Phenylethanolamine
localization of, 18
- β -Phenylethanolamine derivatives
sympathetic nervous system and, 5
- Phenylethanolamine-N methyltransferase
localization of, 18
- Phenylethylamine
localization of, 18
- Phosphogluconate acid
amphetamine metabolism and, 7
- Phosphoinositides
metabolism of
vascular smooth muscle and, 396-97
- Phospholipids
methylation of
signal transduction and, 22
- Phthalic anhydrides
drug-carrier conjugates of, 369
- Pineal gland, 19-22
- Pirenzipine
gastric acidity and, 269-70
- Plasmin
cerebrovasospasm and, 323
- Platelet aggregation
endothelium and, 44-45
ketanserin and, 43-44
serotonin and, 45
- Pneumonitis
drug allergy and, 368
- Poikilothermia, 431
- Polymethyl-C
human immunodeficiency virus and, 419
- Porphyrians
benzodiazepine recognition sites and, 455
- Positron emission tomography
neurotransmitter biochemistry and, 214-26
- Potassium
cerebrovasospasm and, 320, 323
renin secretion and, 107
- Potassium channel blockers
palytoxin and, 146
- Prazosin
ischemic heart disease and, 52
- Prodynorphin, 123
- Progesterone
nasal administration of
cerebrospinal fluid and, 32-33
- Prolactin
erythropoietin production and, 111
neuromodulatory action of, 164
opioids and, 128
secretion of
neuroleptics and, 350-54
- Promin
See Glucosulfone sodium
- Prooxidants
natural, 202-3
xenobiotic, 199-202
- Propranolol
blood-brain barrier and, 31, 33
erythropoietin production and, 112
ischemic heart disease and, 52
- Prostaglandins
anorectic effect of, 250
cerebrovasospasm and, 323
cyclosporine A and, 339
- duodenal ulcer and, 270
erythropoietin production and, 111
- Prostaglandin synthetase
host antioxidant defense and, 194
- Protein kinase
cyclosporine A and, 338
melatonin synthesis and, 21
- Protein kinase A
erythropoietin production and, 103-4
- Protein kinase C
vascular smooth muscle and, 396
- Proteinurea
suramin and, 420
- Prithionamide
leprosy and, 240
- Pseudomonas aeruginosa*
chloramphenicol-resistant, 86
- Pseudopregnancy
neuropeptides and, 165
- Psychotropics
high-affinity recognition sites of, 451-70
- Ptychodus brevis*
toxin of, 142-43
- Pulmonary edema
interstitial
doxorubicin and, 200
- Purines
benzodiazepine recognition sites and, 455
- Purkinje fibers
action potential plateau in tetrodotoxin and, 61-62
delayed rectifier in, 62-63
pacemaker potential of, 63-68
- Q
- Quinidine
cardiac delayed rectifier and, 63
early afterdepolarizations and, 72-75
- Purkinje fiber inward current and, 64
- Quinine
palytoxin and, 146
- Quinones
reactive oxygen metabolites and, 191
- R
- Ranitidine
gastric acidity and, 270
- Raynaud's phenomenon
scleroderma and, 53-54
serotonin and, 53-54

- Reactive oxygen metabolites, 190-92
cancer and, 204
Red tide, 142
Renin
secretion of, 107
Reserpine
depression and, 16-17
neurotransmitter release and, 295-96
serotonin N-acetyltransferase and, 21
tyrosine hydroxylase and, 17
Respiration
dynorphin and, 127
Reverse transcription
human immunodeficiency virus and, 419-23
Rhamnose
satiatin and, 253-54
Ribavirin
human immunodeficiency virus and, 421
Rickettsia
chloramphenicol and, 84
Rifampin
- S
- Salmonella
chloramphenicol and, 84
Satiatin
anorectic effect of, 253-63
Saxitoxin, 141
Scaritoxin, 144
- Selenium-dependent glutathione peroxidase, 193-94
Serotonergic transmission
modulation of, 465-69
Serotonin, 41-55
arterial collateral blood vessels and, 47-50
atherosclerosis and, 46-47
cerebral blood supply and, 53
cerebrovasospasm and, 320, 323
cinanserin and, 48
coronary artery tree and, 50-53
coronary artery vasoconstriction and, 52
digital circulation and, 53-54
endogenous
measurement of, 10
endothelium and, 44-46
erythropoietin production and, 111
hypertension and, 42-43
hypococholesterolemia and, 47
measurement in brain nuclei, 18
metabolism of, 19
platelet aggregation and, 45
platelet-vessel wall interactions and, 43-44
Raynaud's phenomena and, 53-54
renal circulation and, 54-55
thermoregulation and, 431-32
Serotonin N-acetyltransferase
β-receptor and, 21
Serotonin receptor
ketanserin and, 42
Serotonin rhythm
circadian, 20
Serum sickness
drug allergy and, 368, 374
Sexual behavior
hyperprolactinemia and, 354
Sinus node
antiarrhythmics and, 64-65
Skeletal muscle
palytoxin and, 146
SKF525A
drug metabolism and, 8
Smooth muscle
palytoxin and, 146
vascular
calcium channels in, 393-96
calcium extrusion pump and, 403
cell membrane receptors of, 393
hypertension and, 389-404
phosphoinositide metabolism and, 396-97
- sensitivity of, 391-93
sodium-calcium exchanger and, 397-98
sodium-hydrogen exchanger and, 402-3
sodium-potassium pump and, 398-402
- Sodium channel
brevetoxin and, 142-43
ciguatoxin and, 144
sea anemone toxins and, 148-49
- Sodium current
tetrodotoxin-sensitive
Purkinje fibers and, 61-62
- Sodium-potassium pump
palytoxin and, 146
vascular smooth muscle and, 398-402
- Somatostatin
anorectic effect of, 250
brain capillary endopeptidase and, 30
neuromodulatory action of, 164
neurosecretion of
dopamine and, 355
prolactin secretion and, 353
- Spasmogens
cerebrovasospasm and, 323-24
toxicity of, 324
- Spectrofluorometry, 10
- Spinal cord
dynorphin and, 125-26
- Spinal reflexes
neuropeptides and, 165
- Steroid hormones
blood-brain barrier and, 30-31
- Streptococcus pneumoniae*
chloramphenicol and, 84
- Streptococcus viridans*
chloramphenicol and, 84
- Stress
dynorphin and, 129
β-endorphin and, 129
- Striatoxin, 150, 154
- Stroke
opioid peptides and, 129
- Subarachnoid hemorrhage
cerebrovasospasm and, 53, 311
chronic cerebrovasospasm and, 318-21
- Substance P
dynorphin and, 129
endothelium and, 45
neuromodulatory action of, 164
serotonergic neurons and, 288

- Sucralfate
duodenal ulcer and, 270
- Superoxide dismutase
antiinflammatory effects of, 205
- host antioxidant defense and, 192-93
- Suramin
human immunodeficiency virus and, 420
- Sympathomimetic amines, 5-6
norepinephrine uptake and, 16
- T**
- Taurine
host antioxidant defense and, 196
- Tessulatoxin, 150, 154-55
- Testosterone
erythropoietin production and, 111
narcotic demethylation and, 9
- Tetraethylammonium
Purkinje fiber action potentials and, 73
- Tetrodotoxin, 141
palytoxin and, 146
Purkinje fibers and, 61-62
sea anemone toxins and, 149
- Thalidomide
leprosy and, 240
- Thermoregulation, 430-32
opioid peptides and
endogenous, 439-41
exogenous, 432-39
- Thiamphenicol, 83
actions of, 87-88
bone marrow suppression and, 88
DNA and, 90
structure of, 85
- Thiophan
thermoregulation and, 440
- Thioxanthines
antipsychotic potency of, 347
- Thrombin
cerebrovasospasm and, 323
toxicity of, 324
- Thrombocytopenia
drug allergy and, 368
- Thromboxane
cerebral blood supply and, 53
cerebrovasospasm and, 323
- Thromboxane A₂, 42
arterial collateral blood vessels and, 50
platelet-vessel wall interactions and, 43-44
- Thromboxane B₂
- ischemic heart disease and, 52
- Thromboxane synthetase
platelet activation and, 52
- Thyroid hormones
blood-brain barrier and, 27-29
- Thyrotropin
secretion of
neuroleptics and, 356-58
- Thyrotropin releasing hormone
anorectic effect of, 250
neuromodulatory action of, 164
serotonergic neurons and, 288
- Thyroxine
erythropoietin production and, 111
- T lymphocytes
thyroid potentiating factor of, 110
- human immunodeficiency virus and, 411-12
immunogens and, 371-72
- Tobacco smoke
cytotoxicity of, 201-2
- Tobramycin
nephrotoxicity of, 332-33
- Tocopherols
host antioxidant defense and, 197
- Torsion dystonia neuroblastoma
dopamine β -hydroxylase and, 15
- Transcytosis
receptor-mediated
blood-brain barrier and, 29
- Transferrin
blood-brain barrier and, 29
host antioxidant defense and, 196
- Trauma
dynorphin and, 129-30
- Trichloroacetic acid
satiation and, 253
- Triiodothyronine
isomers of
biologic potency of, 28-29
- Trypsin
erythropoietin and, 102
- Tryptamine
localization of, 18
- Tryptophan
melatonin synthesis and, 20
- Tyramine
localization of, 18
norepinephrine uptake and, 16
- 3-methoxy Tyramine, 13
- Tyrosine
- catecholamine synthesis and, 223
- Tyrosine hydroxylase
nerve firing and, 17
- U**
- Uric acid
host antioxidant defense and, 195
- Uridine diphosphate glucuronic acid
enzymatic synthesis of, 10
- Urticaria
drug allergy and, 368, 372, 374
- V**
- Vascular smooth muscle
calcium channels in, 393-96
calcium extrusion pump and, 403
- cell membrane receptors of, 393
- hypertension and, 389-404
phosphoinositide metabolism and, 396-97
- sensitivity of, 391-93
- sodium-calcium exchanger and, 397-98
- sodium-hydrogen exchanger and, 402-3
- sodium-potassium pump and, 398-402
- Vasculitis
drug allergy and, 368, 374
- Vasoactive intestinal peptide
anorectic effect of, 250
brain capillary adenyl cyclase and, 30
coexistence with acetylcholine, 286
neuromodulatory action of, 164
- Vasodilators
chronic, irreversible cerebrovasospasm and, 315-16
- Vasopressin
blood-brain barrier and, 30
dynorphin and, 128
erythropoietin production and, 111
neuromodulatory action of, 164
- V8-protease
erythropoietin and, 102

- V**
- Verapamil
eburnetoxin and, 154
maitotoxin and, 144
tessulatoxin and, 155
- Veratridine
sodium channel and, 143
- Vitamin C
host antioxidant defense and, 195
- Vitamin E
antioxidant role of, 200
gentamicin-induced lipid peroxidation and, 334
oxygen toxicity and, 203
tobacco smoke and, 201-2
- W**
- Water
blood-brain barrier transport of, 30
- Wilson's disease
caeruloplasmin deficiency and, 206
- X**
- Xanthine
reactive oxygen metabolites and, 190
- Xenobiotic prooxidants, 199-202
- Y**
- Yohimbine
ischemic heart disease and, 52
- Z**
- Zimelidine
coexisting neurotransmitters and, 301-2
- Zoanthoxanthins, 145
- Zollinger-Ellison syndrome
drugs for, 270
hypergastrinemia of, 269, 281